


# AMENDMENTS TO THE CLAIMS

Claims 1-15 have been cancelled and new claims 16-26 have been added. A listing of the claims follows and replaces all prior listing of the claims.

## LISTING OF THE CLAIMS


Claims 1-15 (Cancelled).

Claim 16 (New): A  $\beta$ -lactamase resistant cephalosporin ester compound represented by formula (I) as follows:



wherein,

when R is




, R<sub>1</sub> is




(YR-1)

when R is



, R<sub>1</sub> is




(YR-2)

Amendment


(10/580,561)

when R is




, R<sub>1</sub> is —CH<sub>3</sub> (YR-3)

when R is




, R<sub>1</sub> is —CH<sub>3</sub> (YR-4)

when R is



, R<sub>1</sub> is —CH<sub>3</sub> (YR-5)

or, when R is



, R<sub>1</sub> is —Cl (YR-6)

Claim 17 (New): A pharmaceutical salt of the compound according to claim 16.

Claim 18 (New): The pharmaceutical salt of the compound according to claim 17, wherein the pharmaceutical salt is an inorganic salt or an organic acid salt.

Claim 19 (New): The pharmaceutical salt of the compound according to claim 18, wherein the inorganic salt or organic acid salt is at least one of a hydrochloride, a sulphate, a *p*-toluenesulfonate, a tartrate, a maleate and a lactate.

Claim 20 (New): A method for treating infection, comprising:

administering orally to a patient in need of treatment, an effective amount of a composition comprising the compound according to claim 16 as an effective ingredient.

Claim 21 (New): A composition, comprising:

the compound according to claim 16; and  
a physiologically acceptable carrier.


Claim 22 (New): A method for treating infection, comprising:




administering orally to a patient in need of treatment, an effective amount of a composition comprising the pharmaceutical salt according to claim 17 as an effective ingredient.

Claim 23 (New): A composition, comprising:


the pharmaceutical salt according to claim 17; and  
a physiologically acceptable carrier.

Claim 24 (New): A intermediate compound represented by formula (IV) as follows:




wherein,  $R_1 = CH_3$  or  $Cl$ ;  $R_2 =$  ,  or 

Claim 25 (New): A pharmaceutical salt of a  $\beta$ -lactamase resistant cephalosporin ester compound in which the a  $\beta$ -lactamase resistant cephalosporin ester compound is represented by formula (I) as follows:



wherein,

when R is




, R<sub>1</sub> is




(YR-1)

when R is




, R<sub>1</sub> is



(YR-2)

when R is




, R<sub>1</sub> is



(YR-3)

when R is




, R<sub>1</sub> is



(YR-4)

when R is




, R<sub>1</sub> is



(YR-5)

or, when R is



, R<sub>1</sub> is



(YR-

6), and

wherein the pharmaceutical salt is an inorganic salt or an organic acid salt of the  $\beta$ -lactamase resistant cephalosporin ester compound represented by formula (I) and is at least one of a hydrochloride, a sulphate, a *p*-toluenesulfonate, a tartrate, a maleate and a lactate.

Claim 26 (New): A method for treating infection, comprising:

administering orally to a patient in need of treatment, an effective amount of an antibiotic composition comprising the pharmaceutical salt according to claim 25 as an effective ingredient.

Claim 27 (New): An antibiotic composition, comprising:

the pharmaceutical salt according to claim 25; and  
an incipient suitable for oral administration.